Buy & Sell Diageo plc (DEO) – Diageo plc Price Today
Aura AI Summary
Key Stats
- $47.05BMarket Cap
- TechnologySector
- -29.05%3M Drawdown
- $67.87BEnterprise Value
- 3.94%Dividend Yield
- 41 daysTypical Hold Time
Diageo plc (DEO) is currently valued at a market capitalization of $47.05B, with an enterprise value of $67.87B. Over the past 52 weeks, Diageo plc has traded between a low of $72.47 and a high of $115.33, highlighting its annual price range. Over the past three months, Diageo plc has recorded a drawdown of -29.05%, reflecting recent price volatility. Diageo plc offers a dividend yield of 3.94%, with the most recent dividend of $0.80 paid on 17 Apr 26. On average, investors hold Diageo plc for approximately 41 days, indicating typical investor behavior on the platform.
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Most Recent News
BC launches Outdoor Sector Coalition to boost economy, health, and conservation of its outdoors.
A coalition of over 2,000 organizations in British Columbia has formed to support the province's outdoor sector, which is a $17 billion industry employing 80,000 people. The coalition aims to enhance health benefits, support outdoor businesses, and p...

Nvidia's Q1 2027 earnings face high expectations amid strong past beats but mixed stock reactions.
Nvidia is set to report its Q1 2027 earnings with Wall Street expecting $78.8 billion in revenue and $1.77 EPS, marking record growth. Historically, Nvidia has consistently beaten revenue and EPS estimates, but recent earnings have shown that the sto...

ESR1-mutated metastatic breast cancer market to grow 9.6% CAGR with new oral SERDs and targeted therapies.
The ESR1-mutated metastatic breast cancer market is projected to grow rapidly at a 9.6% CAGR from 2026 to 2036, driven by rising cases of endocrine-resistant HR-positive/HER2-negative breast cancer and advances in precision oncology. Novel therapies ...
